U.S. License Holder:
Human Genome Sciences Inc.
Date of License:
December-14-2012
Last Update:
July-08-2024
FDA-Approved Indications
RAXIBACUMAB is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.